DMTTF News and Press, Small Pharma

2024-03-27 17:08:02 ET The world is facing a mental health crisis. Today, one in six individuals are likely to suffer from an episode of major depression during their lifetime that could significantly impact their relationships, work and health. Add to that the substantial negative impact t...

2024-03-27 17:08:02 ET Help for mental health sufferers Small Pharma is a neuropharmaceutical company. They specialize in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into DMT-assiste...

2023-10-23 15:05:20 ET More on Cybin Cybin Inc. 2023 FQ1 - Results - Earnings Call Presentation Psychedelic drugs market to break $7B in 2029 led by these 3 meds Cybin in pact to support training in Phase 3 psychedelic trial Seeking Alpha’s Quant Ratin...

Cybin (NYSE American: CYBN) (NEO: CYBN) together with Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF) announced the completion of the previously disclosed acquisition by Cybin of Small Pharma by way of a plan of arrangement under the Business Corporations Act (British Columbia), and pursuant to ...

This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023. - Combined portfolios create the industry’s largest, most adv...

2023-10-19 17:20:09 ET More on Small Pharma Small Pharma Inc. 2023 Q1 - Results - Earnings Call Presentation Cybin buys psychedelic-based treatment developer Small Pharma Financial information for Small Pharma For further details see: Small Pharma reports...

• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma, supporting the combined company’s vision to build an international clinical-stage leader in psychedelic-based therapeutics LONDON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. ...

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage biopharma...

• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma LONDON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focus...

LONDON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the “ Company ”) between September 25, 2023 and September 27, 2023 at an average price of $0.177 per common share for aggregate proc...